Insights From Pharma 2025: Preparing For Change: Rare Disease Launches In The Era Of EU Health Technology Assessment (HTA)

Change is the only constant in the pharmaceutical world, and the advent of the EU Health Technology Assessment (HTA) marks a pivotal moment for rare disease launches. Pharma 2025 in Barcelona served as a crucial forum for industry leaders to dissect the implications of this regulatory shift. Among the vital discussions was a deep dive between Chiesi's Diana Sinkevich and Cencora's Ruairi O’Donnell, exploring the specific challenges and opportunities facing rare disease products. Their expert perspectives shed light on the need for innovative evidence generation, organizational agility, and a keen understanding of the evolving access landscape.

Uncover the key insights from their conversation by reading the full article.